BDKRB1 and brain neoplasm: We also explored whether a B1R agonist can enhance bioavailability of the chemotherapeutic agent Carboplatin (and Magnevist used as reference) in brain tumor tissues using inductively coupled plasma-mass spectroscopy (ICP-MS).